Health Minister Announces 60-Day Deadline to Barcode Every Medicine Sold in Pakistan

Pakistan has a counterfeit medicine problem. It is not new, it is not small, and it is not theoretical. Substandard and fake drugs have caused patient harm, eroded trust in the pharmaceutical supply chain, and complicated the work of doctors and pharmacists who cannot always verify whether the product in front of them is what its packaging claims it to be. The government has acknowledged the problem in various policy documents over the years. What has been missing is a practical, scalable mechanism for addressing it at the point of sale. Federal Health Minister Syed Mustafa Kamal announced that Pakistan has one now, a medicine barcode system that goes live within 60 days.

What the Minister Announced

Speaking at an event during his visit to the Pakistan Pharmaceutical Manufacturers Association headquarters in Karachi, Minister Kamal announced that all preparations for a nationwide barcode system for medicines have been completed by the Ministry of Health and relevant institutions. The rollout, he said, will happen within the next 60 days.

The barcode system is designed to do three things simultaneously: enable complete traceability of medicines through the supply chain, ensure that patients have access to genuine drugs, and provide a mechanism for eliminating fake products from the market.

The underlying logic is straightforward. A barcode on every medicine package creates a digital record that links that specific product to its manufacturer, batch number, production date, and distribution pathway. Anyone in the chain, manufacturer, distributor, pharmacist, or patient, can scan the code and verify whether the product is legitimate. A counterfeit drug either carries no barcode, a duplicated barcode, or a barcode that does not match any record in the system, making it identifiable rather than invisible.

Why This Reform Is Overdue

Pakistan currently produces approximately 85 percent of its required medicines domestically, a figure that reflects a genuinely substantial local pharmaceutical manufacturing base. But nearly 99 percent of the raw materials used in that production are imported, primarily from China. That import dependency creates multiple points of vulnerability in the supply chain where substitution, adulteration, or outright fraud can occur before a product even reaches a local manufacturer, let alone a pharmacy shelf.

Minister Kamal flagged this raw material dependency as a major economic challenge in its own right, calling for greater local production of pharmaceutical inputs to reduce reliance on imports. But the barcode initiative addresses a different and more immediate layer of the problem: what happens after medicines are manufactured and enter the distribution system.

Pakistan’s pharmaceutical distribution chain is long and fragmented. Drugs move from manufacturers to wholesale distributors, from distributors to sub-distributors, from sub-distributors to retail pharmacies, and from pharmacies to patients, across thousands of intermediary transactions at each level. Without a traceability mechanism, a counterfeit product can enter this chain at any point and become indistinguishable from a legitimate one by the time it reaches the end consumer.

What Changes for Patients and Pharmacies

For ordinary Pakistanis buying medicines, the barcode system represents something that has not previously existed: a simple, accessible way to verify that the medicine they are purchasing is what it claims to be. A smartphone scan, whether through a dedicated government app, an existing health platform, or a general barcode reader linked to a verified database, could tell a patient or a pharmacist within seconds whether a product’s barcode matches a legitimate manufacturer record.

This is not a hypothetical benefit. In countries where medicine barcode and serialisation systems have been implemented, the European Union’s Falsified Medicines Directive, India’s drug traceability initiative, and Turkey’s pharmaceutical track-and-trace system among them, the ability to scan a medicine at the point of dispensing has directly resulted in the detection and removal of counterfeit and substandard products that would otherwise have reached patients.

For pharmacists, the system creates both a verification tool and a liability protection. A pharmacist who scans a medicine and receives a verified result has documented due diligence. One who does not scan, or who ignores a failed scan result, becomes more clearly accountable if a counterfeit product causes harm.

The 60-Day Timeline: Ambitious or Achievable?

The minister’s 60-day commitment is the detail most worth scrutinising. Nationwide pharmaceutical serialisation systems are technically and logistically complex initiatives. They require manufacturers to integrate barcode printing into their production lines, a central database to register and verify codes, a regulatory enforcement mechanism for products that fail verification, and a user-facing interface for pharmacists and patients to check results.

The minister’s statement that all preparations have been completed by the Ministry of Health and relevant institutions is the critical qualifier. If the backend infrastructure, database, manufacturer integration protocols, and verification platform are genuinely ready, 60 days is a tight but potentially achievable timeline for a phased initial rollout. If the announcement is aspirational rather than operational, the 60-day figure will quietly extend into months or years, as similar reform announcements in Pakistan have done before.

The involvement of the Pakistan Pharmaceutical Manufacturers Association in the announcement is a positive sign. Manufacturer buy-in is essential for a barcode system to function; without cooperation from the production end of the supply chain, there are no legitimate barcodes for the verification system to check against. The fact that the minister made the announcement at PPMA headquarters rather than in a government briefing room suggests the industry side of the implementation has been engaged.

The Broader Digital Health Opportunity

Pakistan’s medicine barcode initiative sits within a wider context of digital transformation in the country’s health sector. A functional drug traceability system generates data on which products move through which distribution channels, where supply chain irregularities cluster, and how consumption patterns vary across regions. That data, properly used, has value well beyond counterfeit detection.

For regulators, it creates a real-time view of pharmaceutical distribution that currently does not exist. For manufacturers, it provides evidence of legitimate supply chain performance that can support export market access. For the health system overall, it is a foundation layer for more sophisticated pharmaceutical management, cold chain monitoring, expiry tracking, and shortage detection that Pakistan’s healthcare infrastructure currently lacks the tools to perform systematically.

The Bottom Line

Pakistan’s counterfeit medicine problem has persisted because it has been profitable, difficult to detect, and inadequately policed at scale. A barcode system does not eliminate the financial incentive to produce fake drugs, but it makes those drugs detectable in a way they have never been before, and it shifts the balance of risk for everyone in the supply chain who handles them. If the 60-day timeline holds, and if the verification infrastructure is as ready as the minister claims, Pakistani patients will soon have something simple and powerful: the ability to scan a medicine before they take it and know whether it is real. That is not a small thing. In a country where substandard drugs have caused genuine harm, it may be one of the most practically important health reforms of recent years.